AGL
agilon health, inc.
$107.47
-0.13 (-0.12%)
At close · Jul 7
Market Cap
$1.88B
Shares
16,683,786
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$107.47
Open$108.00
Day$103.89–110.18
52W$7.48–125.71
Avg vol 30d304K
Short int647K · 3.9% float · 2.5d
Short vol33%
Last earningsMay 6, 2026
DataApr 2021–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+208%
above
Price vs 50-day avg
+29%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
85%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+336%
trailing
YTD return
+524%
this year
Relative strength
+328%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $83 › 200d $35 — 50d above 200d
Institutional flow
Distributing
-53% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.88% of float · ▲ +2.4% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
94 holders — near 3-yr low, contrarian setup
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
−2%
Y/Y
Free cash flow
$-119.0M
Balance sheet
$138.7M
net cash
Quant / Vol
risk profile
Volatility
175%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Year Ended December 31, 2026
Total Revenues
Initiated
$5.68B – $5.81B
prior FY $5.93B
midpoint −3.2% Y/Y
Medical Margin
Initiated
$350M – $400M
Quarter Ended June 30, 2026
Total Revenues
Initiated
$1.44B – $1.48B
prior qtr $1.42B
midpoint +2.4% QoQ
Medical Margin
Initiated
$115M – $130M
Adjusted EBITDA
Initiated
$15M – $25M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+208%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
85%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $83 › 200d $35 — 50d above 200d
Institutional flow
Distributing
-53% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.88% of float · ▲ +2.4% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
94 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $7
Now $107 · 85%
52-wk high $126
vs 200-day avg +208%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $54M | Three Months Ended March 31 | — |
|
|
|||
| Medical Margin | $149M | Three Months Ended March 31 | — |
|
|
|||
| CHF inpatient first-diagnosis rate (current) | 5% | current / Q1 2026 call | — |
| CHF inpatient first-diagnosis rate (prior / prior baseline) | 25% | prior baseline (before program intervention) call | — |
| congestive heart failure (CHF) program markets covered | 90% | Q1 2026 call | — |
| members covered by data pipeline with direct payer data feeds (validated member-level clinical a | 85% | Q1 2026 call | — |
| Total members on the agilon platform | 625,000 | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGL
this stock
agilon health, inc.
|
$1.88B | +523.9% | -2.1% | — | 3.9% |
|
HCA
HCA Healthcare, Inc.
|
$91.09B | -11.9% | +7.1% | 14.1 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.49B | -14.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.77B | +3.8% | -2.3% | 10.7 | 4.7% |
|
DVA
Davita Inc.
|
$14.81B | +103.1% | +6.5% | 21.5 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGL | -6.7% | +11.0% | +336.0% | +0.3% | +523.9% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -7.6% | +9.6% | +328.4% | +0.1% | +514.3% |